Please login to the form below

Not currently logged in
Email:
Password:

Evotec

This page shows the latest Evotec news and features for those working in and with pharma, biotech and healthcare.

Celgene bulks up pipeline again with $2.1bn Prothena deal

Celgene bulks up pipeline again with $2.1bn Prothena deal

It’s also been working with Evotec on therapies for neurodegenerative disorders using the German biotech’s stem cell screening platform, and has accelerated its R&D efforts in CNS after

Latest news

  • Sanofi taps Evotec for new anti-infectives drive Sanofi taps Evotec for new anti-infectives drive

    Evotec has been building capabilities in infectious disease research since acquiring Euprotek (UK) in 2014. ... the progress of novel anti-infectives on Evotec’s platform will be a key success factor”.

  • Fujitsu begins two-year medical AI research project Fujitsu begins two-year medical AI research project

    Partners with Kyoto University on R&D-focused work

  • Evotec invests €15m in AI firm Exscientia Evotec invests €15m in AI firm Exscientia

    Evotec invests 15m in AI firm Exscientia. Funds will help the Scottish group accelerate growth. ... As per the investment, Evotec’s chief operating officer, Dr Mario Polywka, will join Exscientia’s board of directors. .

  • Evotec acquires Aptuit for $300m Evotec acquires Aptuit for $300m

    Evotec acquires Aptuit for $300m. The move expands the group’s leadership in external innovation. ... The acquisition will see Evotec drive its efforts on investigational new drug submissions, integrated drug substance, drug products and commercial

  • GSK signs up to apply AI to drug discovery GSK signs up to apply AI to drug discovery

    Exscientia, which says it's the first company to "automate drug design", is already working with the likes of Evotec in immuno-oncology and Sumitomo Dainippon Pharma and Sunovion Pharmaceuticals in

More from news
Approximately 10 fully matching, plus 23 partially matching documents found.

Latest Intelligence

  • Pharma deals continue to slide Pharma deals continue to slide

    For example, Evotec, the German small molecule development company, is acquiring for $300m the US preclinical development company, Aptuit. ... 400. Aptuit (US). Evotec (DE). Company acquisition. Drug discovery and development to IND submission including

  • Deal Watch December 2016 Deal Watch December 2016

    320. Evotec (Germany). Celgene (US). Discovery collaboration. Induced pluripotent stem cells for neurodegenerative diseases. ... upfront. And although the upfronts are a modest percentage of the headline figure, ranging from < 1% (BioInvent) to 15%

  • Pharma deals in August 2015 Pharma deals in August 2015

    Acquisition of Priority Review Voucher. 350. Evotec. Sanofi. Beta cell modulating treatments for diabetes. ... Acquisition ‐ company. 300. Aperion Biologics Evotec. Sanofi. To develops mall molecule immuno‐ therapies.

  • Deal Watch table for December 2014 Deal Watch table for December 2014

    Company acquisition. 375. Evotec / Sanofi. R&D alliance to progress Sanofi discovery phase compounds to preclinical stage (inc Sanofi discovery facility with 200 scientists).

  • Deal Watch table for November 2013 Deal Watch table for November 2013

    130. Evotec /Janssen. R&D collaboration. Target AD collaboration to identify novel therapies for Alzheimer's.

More from intelligence
Approximately 0 fully matching, plus 8 partially matching documents found.

Latest appointments

More from appointments
Approximately 1 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Aptus Health

Aptus Health is dedicated to advancing health engagement. The company offers end-to-end digital health engagement solutions spanning all areas of...

Latest intelligence

No incentive for a cure
The paradox of ‘cost-effective but unaffordable’ life-saving medicines...
Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...

Infographics